Skip to main content
Clinical Trials/NCT01574872
NCT01574872
Withdrawn
Phase 2

Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis

Tecno Sun SRL1 site in 1 countryMarch 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Inverse Psoriasis
Sponsor
Tecno Sun SRL
Locations
1
Primary Endpoint
Percent change from baseline of PASI index equal to or greater than 50% (PASI50 +)
Status
Withdrawn
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy of Aerosal® compared to placebo in the prognosis of inverse psoriasis or sebopsoriasis present for at least one year

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
April 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Tecno Sun SRL
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Inverse Psoriasis or Sebopsoriasis lasting from at one year
  • At least 1% of total body surface area involvement Suspension for more than 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporin, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)

Exclusion Criteria

  • Patients with acute bronchopulmonary disease, tuberculosis, severe hypertension, hyperthyroidism, cancer (chemotherapy), intoxication, heart failure
  • Iodine allergy
  • Women who are pregnant or planning to become pregnant during the study

Outcomes

Primary Outcomes

Percent change from baseline of PASI index equal to or greater than 50% (PASI50 +)

Time Frame: 3 weeks (15 sessions), 15 weeks

Secondary Outcomes

  • Overall patient satisfaction(3 weeks (15 sessions), 15 weeks)
  • Any change from baseline of physician's clinical judgment(3 weeks (15 sessions), 15 weeks)
  • Number of reported adverse events(3 weeks (15 sessions), 15 weeks)
  • Any change from baseline of PASI index(3 weeks (15 sessions), 15 weeks)

Study Sites (1)

Loading locations...

Similar Trials